Dendritic cell–mediated antigen presentation

Dendritic cell–mediated antigen presentation is the primary process by which dendritic cells capture, process, and present antigens to T cells, serving as a crucial bridge between innate and adaptive immunity. DCs are uniquely specialized to activate naive T cells through presentation of antigens on major histocompatibility complex (MHC) class I and II molecules, a function that includes the unique ability to cross-present exogenous antigens on MHC class I (cross-presentation)[1][2][3][4][6][8]. This mechanism is essential for effective immune responses against tumors, viruses, vaccines, and for the maintenance of tolerance. Defects or alterations in this process are implicated in immunodeficiency, cancer progression, infection susceptibility, and autoimmunity. While not a molecular drug target itself, many immunotherapeutic strategies aim to enhance or modulate this presentation function to treat disease[2][4][5][6][8]. For most drug-targeting and structural biology use cases, the actual therapeutic molecular targets would be the specific molecules involved in this process, such as MHC molecules (e.g., HLA-A, HLA-DR), costimulatory receptors (CD80, CD86), or DC-specific molecules (e.g., DEC-205).

Other names

Antigen presentation by dendritic cellsDC-mediated antigen presentationDendritic cell antigen presentationDendritic cell cross-presentation (when referring specifically to cross-presentation)

Enhancement or modulation of dendritic cell antigen presentation leads to improved T cell priming and activation